News stories about Harvard Bioscience (NASDAQ:HBIO) have been trending somewhat positive on Saturday, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Harvard Bioscience earned a media sentiment score of 0.03 on Accern’s scale. Accern also assigned press coverage about the medical instruments supplier an impact score of 46.5341107583854 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
HBIO has been the topic of several research reports. Zacks Investment Research upgraded shares of Harvard Bioscience from a “hold” rating to a “buy” rating and set a $5.25 price objective on the stock in a report on Thursday, March 8th. Janney Montgomery Scott increased their target price on shares of Harvard Bioscience from $5.00 to $8.00 and gave the company a “buy” rating in a report on Wednesday, January 24th. Benchmark increased their target price on shares of Harvard Bioscience from $6.00 to $10.00 and gave the company a “buy” rating in a report on Tuesday, January 23rd. Finally, ValuEngine upgraded shares of Harvard Bioscience from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. One research analyst has rated the stock with a hold rating and three have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $7.75.
HBIO stock opened at $5.00 on Friday. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.39 and a quick ratio of 1.86. Harvard Bioscience has a 12 month low of $2.30 and a 12 month high of $5.40. The company has a market capitalization of $177.97, a PE ratio of 100.00 and a beta of 1.28.
In other Harvard Bioscience news, CEO Jeffrey Duchemin sold 87,022 shares of Harvard Bioscience stock in a transaction that occurred on Friday, March 9th. The shares were sold at an average price of $4.53, for a total transaction of $394,209.66. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director George Uveges sold 35,054 shares of Harvard Bioscience stock in a transaction on Wednesday, March 7th. The stock was sold at an average price of $4.61, for a total transaction of $161,598.94. The disclosure for this sale can be found here. Insiders sold 241,413 shares of company stock worth $1,106,256 over the last ninety days. 9.80% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY WARNING: “Harvard Bioscience (NASDAQ:HBIO) Getting Somewhat Favorable News Coverage, Study Shows” was originally reported by BBNS and is the property of of BBNS. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://baseballnewssource.com/2018/04/07/harvard-bioscience-hbio-earning-somewhat-positive-media-coverage-accern-reports/2038214.html.
Harvard Bioscience Company Profile
Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors.
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.